Composition
inf/Inj 20 mg:Mitoxantrone HCI 20 mg; solutionn in vial.
Indications & Dosage
Metastatic breast cancer, Non-Hodgkins lymphoma, Adult acute non-lymphocytic leukaemia, Non-resectable primary hepatocellular carcinoma, ovarian carcinoma: BY IV INF: Adult: 12 mg/m2 every 3 months.
Administration
Mitoxantrone HCI is administered by slow IV infusion after dilution to at least 50 ml in D5W or NS over 15 to 30 min through the tubing of a freely running IV solution or by continuous IV infusion over 24 hours. It should not be given over less than three min.
Compatibility
Stable in D5NS, D5W, NS. Incompatible with amphotericin B cholesteryl sulphate complex, aztreonam, cefepime, doxorubicin liposome, paclitaxel, piperacillin/ tazobactam, propofol Y-site administration: Incompatible with heparin when admixed.
Stability
Store intact vials at 15C-25C (59F-77F). Do not freeze. Opened vials may be stored under refrigeration for up to 7 days or at room temperature for 14 days. Solutions diluted for administration are stable for 7 days at room tem-perature or under refrigeration.
Precautions
Patients with pancytopenia or severe infections, severe hepatic and/or renal insufficiency, severe heart disease (avoid) and those previously treated with anthracyclines and/or irradiated on mediasti-num. Monitor hematological blood parameters before each application as well as at least once during each treatment cycle. Caution is necessary with concomitant use of cardiotoxic drugs, or drugs that reduce cardiac contractility. Cardiac function should be monitored closely
Interactions
Anti-neoplastic drugs.
Pregnancy
Positive evidence of risk: Avoid
Lactation
Contraindicated. Discontinue breast-feeding
Side Effects
Abdominal pain, alopecia, amenorrhoea, Anorexia, anxiety, blue discoloration of nails and skin, bone-marrow suppression, confusion, constipation, diarrhoea, cardiotoxicity, drowsiness, dyspnea, extravasation, GI bleeding, hyperuricaemia, myelosuppression, nausea, oral mucositis, paraesthesia, thromboembolism, transient blue-green discoloration of urine, tumourlysis syndrome, vomiting